Abstract
Chemotherapy, the standard of care treatment for cancer patients with advanced disease, has been increasingly recognized to activate host immune responses to produce durable outcomes. Here, in colorectal adenocarcinoma (CRC) we identify oxaliplatin-induced Thioredoxin-Interacting Protein (TXNIP), a MondoA-dependent tumor suppressor gene, as a negative regulator of Growth/Differentiation Factor 15 (GDF15). GDF15 is a negative prognostic factor in CRC and promotes the differentiation of regulatory T cells (Tregs), which inhibit CD8 T-cell activation. Intriguingly, multiple models including patient-derived tumor organoids demonstrate that the loss of TXNIP and GDF15 responsiveness to oxaliplatin is associated with advanced disease or chemotherapeutic resistance, with transcriptomic or proteomic GDF15/TXNIP ratios showing potential as a prognostic biomarker. These findings illustrate a potentially common pathway where chemotherapy-induced epithelial oxidative stress drives local immune remodeling for patient benefit, with disruption of this pathway seen in refractory or advanced cases.
Introduction
Colorectal adenocarcinoma (CRC) remains a leading cause of cancer mortality worldwide. While oxaliplatin-based chemotherapy is a first-line standard of care, clinical responses among patients vary significantly. Historically, chemotherapy was viewed primarily as a cytotoxic agent that kills rapidly dividing cells. However, modern oncology has shifted toward a paradigm where successful treatment often requires the "awakening" of the host's immune system.
The central challenge in CRC treatment is understanding why some tumors remain "cold" (immunosuppressive) despite treatment, while others transition to a "hot" (immune-active) state. This study identifies a molecular "switch"—the TXNIP/GDF15 axis—that determines whether colorectal cancer responds to oxaliplatin. By triggering oxidative stress, the treatment activates a MondoA-dependent pathway that suppresses immunosuppressive signals, effectively remodeling the tumor microenvironment.
Methodology and Data Integration
The researchers employed a multi-disciplinary approach to map the signaling hierarchy and validate its clinical relevance:
- Experimental Modeling: The study utilized standard CRC cell lines (DLD1, HCT15) alongside advanced Patient-Derived Tumor Organoids (PDTOs) to simulate real-world tumor responses in a 3D environment.
- Genetic and Molecular Analysis: CRISPR-Cas9 and siRNA were used to knock out key components, including TXNIP, MondoA (MLXIP), and GDF15. ChIP-PCR confirmed that the transcription factor MondoA directly binds to the TXNIP promoter.
- Multi-omics Profiling: RNA-seq and Mass Spectrometry were used to identify transcriptomic changes and secreted factors, respectively.
- Clinical Validation: The team analyzed matched pre- and post-treatment biopsies from CRC patients and utilized a 94-sample tissue microarray (TMA) for protein-level validation.
The study integrated several high-value datasets, including TCGA COAD for broad transcriptomic analysis, GSE132465 for single-cell RNA-seq verification, and multiple validation microarrays (e.g., GSE28702, GSE29621) to test the predictive power of the proposed biomarker.
Key Insights: The TXNIP/GDF15 Axis
The study revealed a specific pathway mediated by oxidative stress:
- ROS Sensing: Oxaliplatin induces Reactive Oxygen Species (ROS). The transcription factor MondoA acts as a sensor for this stress, translocating to the nucleus to drive the expression of TXNIP, a known tumor suppressor.
- Suppression of GDF15: TXNIP acts as a negative regulator of GDF15, a secreted factor that typically promotes the differentiation of Regulatory T cells (Tregs). These Tregs inhibit the activation of "killer" CD8+ T cells.
- Immune Remodeling: In responsive tumors, oxaliplatin increases TXNIP and decreases GDF15, reducing Treg activity and allowing for a robust anti-tumor immune response.
- Resistance Mechanism: In advanced or resistant disease, this axis is disrupted. These tumors fail to upregulate TXNIP in response to chemotherapy, allowing GDF15 levels to remain high and maintaining an immunosuppressive environment.
Results and Clinical Implications
The findings suggest that the TXNIP/GDF15 axis is a potent predictor of patient outcomes:
- Survival Correlation: High TXNIP and low GDF15 levels are significantly associated with better overall survival in CRC patients ($p=0.0027$ and $p=0.0468$, respectively).
- Biomarker Potential: The GDF15/TXNIP ratio proved to be a strong biomarker. A high pre-treatment ratio predicted a poor response to oxaliplatin with an Area Under the Curve (AUC) of 0.73 ($p=0.0076$).
- Mechanistic Specificity: GDF15 was found to induce the expression of the Treg marker Foxp3 via the CD48 receptor. Notably, this mechanism appears specific to oxaliplatin; other common drugs like 5-FU or SN38 did not trigger the same TXNIP/GDF15 response.
Limitations and Future Directions
While the study establishes a clear pathway (ROS → MondoA → TXNIP ⊣ GDF15), the exact molecular mechanism by which TXNIP suppresses GDF15 remains to be fully elucidated. The authors hypothesize that the oncogene MYC may be a missing link, given TXNIP's known role in antagonizing MYC genomic binding.
Furthermore, the study notes that ARRDC4, a paralog of TXNIP, likely provides some functional redundancy. Future research must validate the GDF15/TXNIP ratio in prospective clinical trials to determine if it can guide treatment decisions, potentially steering non-responders toward alternative therapies, such as GDF15 antagonists, earlier in their clinical course.
Summary updated